Author:
Bian Zhuoqiong,Wu Xiaoling,Chen Qing,Gao Qing,Xue Xiang,Wang Yidong
Abstract
Abstract
Background
Cervical cancer is a common malignant tumor in the female. Interleukin (IL)-17A is a proinflammatory factor and exerts a vital function in inflammatory diseases and cancers. M2 macrophage has been confirmed to promote tumor development. Nevertheless, it is not yet known whether IL-17A facilitates cervical cancer development by inducing M2 macrophage polarization. Therefore, this study was conducted to investigate the regulatory effect of IL-17A on M2 macrophage polarization and the underlying mechanism in cervical cancer development.
Methods
RT-qPCR was utilized for testing IL-17A expression in cancer tissues and cells. Flow cytometry was applied to evaluate the M1 or M2 macrophage polarization. Cell proliferative, migratory, and invasive capabilities were measured through colony formation and transwell assays. ChIP and luciferase reporter assays were applied to determine the interaction between IL-17A and octamer-binding transcription factor 4 (OCT4).
Results
IL-17A expression and concentration were high in metastatic tissues and cells of cervical cancer. IL-17A was found to facilitate M2 macrophage polarization in cervical cancer. Furthermore, IL-17A facilitated the macrophage-mediated promotion of cervical cancer cell proliferative, migratory, and invasive capabilities. Mechanistic assays manifested that Oct4 binds to and transcriptionally activated IL-17A in cervical cancer cells. Furthermore, Oct4 promoted cervical cancer cell malignant phenotype and M2 macrophage polarization by activating the p38 pathway that, in turn, upregulated IL-17A. Additionally, in vivo experiments confirmed that Oct4 knockdown reduced tumor growth and metastasis.
Conclusion
Oct4 triggers IL-17A to facilitate the polarization of M2 macrophages, which promotes cervical cancer cell metastasis.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Shaanxi Province
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Buskwofie A, David-West G, Clare CA (2020) A review of cervical cancer: incidence and disparities. J Natl Med Assoc 112(2):229–232
2. Sundström K, Elfström KM (2020) Advances in cervical cancer prevention: efficacy, effectiveness, elimination? PLoS Med 17(1):e1003035
3. Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27(4):e43
4. Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084
5. Nowak M, Klink M (2020) The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 9(5):1299